# Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants

> **NCT05556226** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 40 (actual)

## Conditions studied

- ABBV-154

## Interventions

- **DRUG:** ABBV-154 Dose Formulation A
- **DRUG:** ABBV-154 Dose Formulation B

## Key facts

- **NCT ID:** NCT05556226
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-18
- **Primary completion:** 2023-02-17
- **Final completion:** 2023-02-17
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05556226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05556226, "Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05556226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*